Aethlon Medical Announces Financial Results for the Fiscal First Quarter Ended June 30, 2025, and Provides Corporate Update
Australian Cancer Trial Advances with First Cohort Complete, Amended Protocol, and Promising Preclinical Data Published; Operating Expenses Cut by 32% Conference Call to be Held Today at 4:30 p.m. ...
How does the updated corporate outlook align with management's previous guidance and analyst expectations?
What are the potential regulatory hurdles for the trial's amended protocol and how might they impact timelines?
Are there any new collaborations or licensing deals tied to the Australian trial that could boost future earnings?
24 days ago